One of the most important medical advances in recent years could become a reality. The Mosaic study, which carefully analyzes the efficacy of a vaccine in preventing HIV infection, is about to enter the trial phase.
Based on the combination of several virus proteins that are genetically added to a viral vector and that could be harmless to humans, this vaccine, if the results are as expected, could generate immunity against HIV and its different subtypes.
Carlos Cabrera, one of the researchers behind the vaccine, declared that the study is a historic achievement for humanity, underlining that it is the first clinical trial of an HIV vaccine in 10 years to be in stage 3.
Eight countries participate with Argentina, Peru, Mexico, Brazil and the United States on the part of the American continent, and Spain, Italy and Poland on the part of Europe. It is a study that aims to recruit 3,800 volunteer participants around the world.
The researcher also explained that the functioning of the immunizer is only effective in a preventive way, that is, it only works for people who have not yet acquired HIV infection. However, it is still too early to calculate the percentage of effectiveness.
There have already been three other HIV vaccine candidates since the 1980s and, unfortunately, all of them have not reached 30 percent effectiveness. So this is promising, it would probably have that possibility of jumping that barrier, there is even talk that it could be 50 percent.
Check Also: How Much Ben Shapiro Net Worth is in 2021?
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
